Calamos Advisors LLC Makes New Investment in SiBone (NASDAQ:SIBN)

Calamos Advisors LLC bought a new position in shares of SiBone (NASDAQ:SIBN - Free Report) during the first quarter, according to its most recent Form 13F filing with the SEC. The fund bought 65,462 shares of the company's stock, valued at approximately $918,000. Calamos Advisors LLC owned about 0.15% of SiBone at the end of the most recent quarter.

A number of other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. Virtus Fund Advisers LLC acquired a new stake in shares of SiBone during the 4th quarter worth $40,000. GAMMA Investing LLC grew its holdings in shares of SiBone by 20,352.6% during the 1st quarter. GAMMA Investing LLC now owns 3,886 shares of the company's stock worth $55,000 after purchasing an additional 3,867 shares in the last quarter. KLP Kapitalforvaltning AS acquired a new stake in shares of SiBone during the 4th quarter worth $97,000. Johnson Investment Counsel Inc. acquired a new stake in shares of SiBone during the 1st quarter worth $148,000. Finally, Proficio Capital Partners LLC acquired a new stake in shares of SiBone during the 4th quarter worth $155,000. 98.11% of the stock is owned by institutional investors and hedge funds.

SiBone Trading Up 1.8%

SiBone stock traded up $0.34 during trading hours on Thursday, hitting $18.78. The stock had a trading volume of 294,940 shares, compared to its average volume of 392,943. The company has a quick ratio of 7.26, a current ratio of 8.53 and a debt-to-equity ratio of 0.21. The stock has a market cap of $800.31 million, a price-to-earnings ratio of -29.34 and a beta of 0.93. SiBone has a one year low of $11.70 and a one year high of $20.05. The business's 50 day simple moving average is $18.07 and its 200-day simple moving average is $16.26.

SiBone (NASDAQ:SIBN - Get Free Report) last posted its earnings results on Monday, May 5th. The company reported ($0.15) EPS for the quarter, beating the consensus estimate of ($0.24) by $0.09. The firm had revenue of $47.29 million during the quarter, compared to the consensus estimate of $45.13 million. SiBone had a negative return on equity of 16.00% and a negative net margin of 15.03%. On average, equities analysts predict that SiBone will post -0.78 EPS for the current fiscal year.

Insider Buying and Selling at SiBone

In related news, SVP Michael A. Pisetsky sold 3,127 shares of the firm's stock in a transaction that occurred on Wednesday, July 2nd. The stock was sold at an average price of $18.29, for a total transaction of $57,192.83. Following the completion of the sale, the senior vice president owned 261,681 shares of the company's stock, valued at $4,786,145.49. This trade represents a 1.18% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. Also, CFO Anshul Maheshwari sold 5,005 shares of the firm's stock in a transaction that occurred on Wednesday, July 2nd. The stock was sold at an average price of $18.34, for a total value of $91,791.70. Following the sale, the chief financial officer directly owned 217,078 shares of the company's stock, valued at $3,981,210.52. This represents a 2.25% decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 101,702 shares of company stock valued at $1,866,404 over the last ninety days. Insiders own 4.00% of the company's stock.

Wall Street Analyst Weigh In

SIBN has been the topic of several analyst reports. Needham & Company LLC reissued a "buy" rating and set a $24.00 target price on shares of SiBone in a report on Tuesday, May 6th. Cantor Fitzgerald restated an "overweight" rating and set a $25.00 price objective on shares of SiBone in a research report on Tuesday, May 6th. Finally, Truist Financial upped their price objective on SiBone from $20.00 to $22.00 and gave the stock a "buy" rating in a research report on Tuesday, May 6th.

SiBone Profile

SI-BONE, Inc, a medical device company, that operate to solve musculoskeletal disorders of the sacropelvic anatomy in the United States and internationally. It offers proprietary minimally invasive surgical implant system to address sacroiliac joint dysfunction and fusion, adult deformity and degeneration, and pelvic trauma; and implantable bone products.